LSTA:NASDAQ
Lisata Therapeutics, Inc.
0,90 $
arrow_downward
-1,22%(-0,011) 1D
0,90 $
arrow_upward
+0,01% (+0,00010)bedtimeAfter hours
Closed: 20 նոյ, 16:00:00 GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for LSTA...
Open
0,88 $
High
0,90 $
Low
0,85 $
Mkt. cap
9,71 մլն
Avg. vol.
130,45 հզր
Volume
139,29 հզր
52-wk high
5,06 $
52-wk low
0,85 $
EPS
-1,64 $
Beta
1,04
Shares outstanding
10,80 մլն
No. of employees
21
Open
0,88 $
High
0,90 $
Low
0,85 $
Mkt. cap
9,71 մլն
Avg. vol.
130,45 հզր
Volume
139,29 հզր
52-wk high
5,06 $
52-wk low
0,85 $
EPS
-1,64 $
Beta
1,04
Shares outstanding
10,80 մլն
No. of employees
21
News stories
From web sources and news partners
TradingView
·
2 ժամ առաջ
Stock Market Crash: Nasdaq, S&P 500 Suffer Worst Weekly Losses in Years
Traders Union
·
7 ժամ առաջ
VIX fear index hits highest level since April 2025 as S&P 500 plunges
Profile
Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through a merger of Cend Therapeutics and Caladrius Biosciences in September 2022.
In 2019, the FDA granted their product, certepetide, orphan drug status in pancreatic cancer, followed by a Fast track status in 2022. Non-clinical data collected by Lisata and others have demonstrated enhanced delivery of various existing and emerging anti-cancer therapies, including chemotherapies, immunotherapies and RNA-based therapeutics when used with certepetide. Wikipedia
About Lisata Therapeutics, Inc.
CEO-
Employees21
Founded1980
HeadquartersBasking Ridge, Նյու Ջերսի, Միացյալ Նահանգներ
SectorHealth Care
Industry-
Websitelisata.com